FDA Needs New Standards for Studying Alzheimer's Drugs
Category: WELLNESS
In the end, it may turn out that attacking today's biomarkers may not prevent Alzheimer's. The answer, though, won't be known unless the FDA revises its rules, a gamble we may want to take given the alternative.
By Tia Powell, Contributor
Director, Montefiore Einstein Center for Bioethics, 2013-03-22